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Abstract
Two new, rapid, precise, accurate and speciﬁc chromatographic methods were described for
the simultaneous determination of olmesartan medoxomil and hydrochlorothiazide in com-
bined tablet dosage forms. The ﬁrst method was based on reversed phase liquid chroma-
tography using an Eurosphere 100 RP C18 column (250 9 4.6 mm ID, 5 lm). The mobile
phase was methanol–0.05% o-phosphoric acid (60:40 v/v) at a ﬂow rate of 1.0 mL min
-1.
Commercially available tablets and laboratory mixtures containing both drugs were assayed
and detected using a UV detector at 270 nm. The second method involved silica gel 60 F254
high performance thin layer chromatography and densitometric detection at 254 nm using
acetonitrile–ethyl acetate–glacial acid (7:3:0.4 v/v/v) as the mobile phase. Calibration
curves ranged between 200–600 and 125–375 ng spot
-1 for olmesartan and hydrochlo-
rothiazide, respectively.
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Introduction
Olmesartan medoxomil (OLM) is a pro-
drug and hydrolyzed to olmesartan dur-
ing absorption from the gastrointestinal
tract [1–4]. OML is a selective AT1 sub-
type angiotensin II receptor antagonist.
OLM is described chemically as the
(5-methyl-2-oxo-1,3-dioxol-4-yl) methyl
ester of 4-(1-hydroxy-1-methylethyl)
-2-propyl-1-{[20-(1H-tetrazol-5-yl)[1,10-
biphenyl]-4-yl]methyl}-1H-imidazole-5-
carboxylic acid [5, 6]. Hydrochlorothia-
zide (HCT), 6-chloro-3,4-dihydro-2H-
1,2,4-benzothiadiazine-7-sulphonamide
1,1-dioxide, one of the oldest and widely
used thiazide diuretics [7] (Fig. 1).
OLM has not yet been oﬃcially
described in any pharmacopoeia. A
literature survey revealed that several
analytical methods were reported for
the determination of OML in biological
ﬂuids including liquid chromatography
tandem mass spectrometry (LC–MS–
MS), capillary electrophoresis (CE), LC
and high performance thin layer chro-
matography (HPTLC) [8–13]. OLM
determination has been reported for
single preparations or in combination
with other antihypertensive drugs [14,
15]. The USP describes an RP-HPLC
method for the determination of HCT
in tablets. Several analytical methods
have been reported for the determina-
tion of HCT in pharmaceutical for-
mulations including polarography, LC,
HPTLC, and spectroﬂuorometry [16–
26]. A literature survey revealed that
analytical methods have not been re-
ported for the determination of OML
and HCT in a combined tablet for-
mulation. The present study was
therefore aimed to provide such an
economically viable RP-LC and
HPTLC method.
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Apparatus
The HPLC system consisted of a LC
Knauer pump smartline 1000 and a
Knauer manual injector using a 20 lL
ﬁxed loop. A UV/VIS detector was set at
270.0 nm and peak areas were integrated
automaticallyusingChromgatesoftware.
Samples were applied as 8 mm bands by
means of a Camag Linomat V automatic
sample applicator (Muttenz Switzerland)
equipped with a 100 lL syringe. The dis-
tance between the bands was 11.4 mm.
Silica gel 60 F254 HPTLC plates
(20 9 10 cm, aluminum) were from
Merck (Darmstadt, Germany). Densito-
metricscanningwasperformedat254 nm
with a Camag TLC scanner 3 equipped
with Camag Wincats software 1.4.2 using
the deuterium light source and slit
dimensions of 6.00 mm 9 0.45 mm.
Chemicals
Olmesartan medoxomil (OML) and
hydrochlorothiazide (HCT) were kindly
supplied by Ajanta Pharmaceutical Pvt.
(Paithan) and Glen Mark Pharma
(Nashik). All chemicals were of HPLC
grade, methanol and acetonitrile (S d
ﬁne-chem, Mumbai, India), water and
ethyl acetate (Merck, Mumbai, India),
o-phosphoric acid (Qualigens, Mumbai,
India). Commercially available tablets
(Olmesar-H of Macleod, Gujarat, In-
dia), containing 20 mg OML and
12.5 mg HCT per tablet, 12.5 mg tab-
let
-1) were used for analysis.
Stock Solutions of Standard
OLM and HCT for RP-LC
and HPTLC
OLM and HCT stock solutions
(1.0 mg mL
-1) were prepared in metha-
nol. The standard working concentra-
tions of mixed OLM (20 lgm L
-1) and
HCT (12.5 lgm L
-1) were prepared in
the mobile phase using methanol–0.05%
o-phosphoric acid (60:40 v/v). This
solution was subjected to LC analysis. A
10 mL standard working solution con-
taining 200 ng OML and 125 ng HCT
was spotted on the TLC plate.
Reversed Phase High
Performance Liquid
Chromatography
Chromatographic Conditions
Solutions and mobile phases were freshly
prepared prior to use. The mobile phase
consisted of methanol–0.05% o-phos-
phoric acid (60:40 v/v). The analytical
column was an Eurosphere 100 C18
column (250 9 4.6 mm, Knauer, Berlin,
Germany). UV detection was carried out
at 270 nm. Analyses were performed
under isocratic conditions at a ﬂow-rate
of 1.0 mL min
-1. All solvents were ﬁl-
tered through 0.45 lm membrane ﬁlters
and degassed in an ultrasonic bath.
Calibration
For calibration purposes, a range of 4–
24 lgm L
-1 OLM and 2.5–15 lgm L
-1
HCT solutions were prepared and 20 lL
injections were carried out in triplicate.
OLM and HCT sample concentrations
were calculated based on calibration
curves. System suitability tests were also
carried out.
Analysis of Tablet Formulations
Ten tablets were weighed accurately and
powdered. Powder equivalent to 100 mg
OLM and 62.5 mg HCT was weighed
and transferred to a 100 mL volumetric
ﬂask. It was dissolved in 50 mL metha-
nol by shaking the ﬂask for 15 min and
ﬁlled to volume with methanol, followed
by ﬁltration through a 0.45 lm mem-
brane ﬁlter. A ﬁnal concentration of
20 lgm L
-1 of OLM and 12.5 lgm L
-1
of HCT were prepared and concentra-
tions of the OLM and HCT were calcu-
lated from the calibration graph.
Recovery Study
The accuracy of the proposed method
was evaluated by the addition of a
standard drug solution to a pre-analysed
tablet sample solution at three diﬀerent
concentration levels at 80, 100 and 120%
of linearity for both drugs.
High Performance Thin Layer
Chromatography
Chromatographic Conditions
Chromatography was performed on
20 cm 9 10 cm aluminum HPTLC
plates coated with 0.2 mm layers of silica
gel 60 F254 (Merck). Before use plates
were washed with methanol and dried in
an oven at 120 C for 20 min. Ascending
development of the plate with a migra-
tion distance of 70 mm was performed at
23 ± 2 C using acetonitrile–ethyl ace-
tate–glacial acid (7:3:0.4, v/v/v) as the
mobile phase and a Camag twin-trough
2
0
50
26
76
100
126
4681 0 1 4 12
0
50
26
76
100
126
Time (min)
m
A
U
m
A
U
2.8 7.1
S 2600[1]
HCT
OLM
Fig. 1. Representative HPLC chromatogram and structures of olmesartan medoxomil OLM
(20 lgm L
-1) and hydrochlorothiazide HCT (12.5 lgm L
-1)
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bile phase for 20 min. The average
development time was 20 min.
Calibration
Mixed working standard solutions
equivalent to 20, 30, 40, 50, 60 lL were
separately spotted on the TLC plate in
order to obtain ﬁnal OML concentra-
tions at 200, 300, 400, 500, 600 ng spot
-1
and HCT at 125, 187.5, 250, 312.5,
375 ng spot
-1, respectively. The plates
were developed in a 20 9 10 cm twin
through chamber using 20 mL freshly
prepared mobile phase.
Analysis of Tablet Formulation
Ten tablets were weighed, triturated and
the average tablet weight was calculated.
A 1.0 mg mL
-1 solution was prepared in
methanol and ﬁltered through Whatman
ﬁlter paper no. 41. Five mL tablet stock
solution were diluted to 50 mL with
methanol which was used as the working
standard solution. This solution was
spotted (5 lL) on the HPTLC plate to
give a concentration of 500 ng spot
-1 of
OLM equivalent to 312.5 ng spot
-1 of
HCT. Both concentrations were calcu-
lated from the calibration graph.
Recovery Study
The accuracy of the proposed method
was evaluated by the addition of a
standard drug solution to a pre-analysed
tablet sample solution at three diﬀerent
concentration levels at 80, 100 and 120%
of linearity for both drugs.
Results and Discussion
Reversed Phase High
Performance Liquid
Chromatography
A satisfactory separation was obtained
when using methanol–0.05% o-phos-
phoric acid (60:40 v/v) under isocratic
conditions and a ﬂow rate of
1.0 mL min
-1. Peaks were well deﬁned,
resolved and almost free from tailing.
Retention times for OLM and HCT were
observed at 2.8 min and 7.1 min,
respectively (Fig. 1) and the optimum
wavelength was determined to be
270.0 nm.
System suitability tests were also
carried out to verify reproducibility and
results are summarised in Table 1. For
quantitative applications linear calibra-
tion graphs were obtained with correla-
tion coeﬃcients of 0.9998 and 0.9999 for
OLM and HCT, respectively. Limits of
detection (LOD) were 0.44 lgm L
-1 for
OML and 0.21 lgm L
-1 for HCT limits
of quantitation (LOQ) 1.32 lgm L
-1 for
OML and 0.63 lgm L
-1 for HCT,
which showed good precision for the
proposed RP-LC method [26]. The pro-
posed method was used for the deter-
mination of both drugs in tablets and
results are shown in Table 2 indicating
satisfactory recoveries and high preci-
sion.
High Performance Thin Layer
Chromatography
A number of experimental parameters,
such as mobile phase composition, scan
modes and detection wavelengths, were
optimized during method development
in order to provide accurate, precise and
reproducible results for the simultaneous
determination of OML and HCT. Max-
imum separation (OML Rf 0.44, HCT Rf
0.64) and minimum tailing were ob-
tained when using a mobile phase com-
position of acetonitrile–ethyl acetate–
glacial acid (7:3:0.5 v/v/v), respectively
(Fig. 2).
Table 1 shows that correlation coef-
ﬁcients were 0.999 for OML and 0.994
for HCT. The LOD values were 20 ng
spot
-1 for OML and 19 ng spot
-1 for
HCT while LOQ values were 61 and
57 ng spot
-1 for OML and HCT,
respectively. The proposed method was
used for the determination of both drugs
in tablets and results are also shown in
Table 2. Good recoveries and standard
deviations were observed.
Conclusion
The selected methods were found to be
sensitive, reproducible and accurate for
the analysis of olmesartan medoxomil
and hydrochlorothiazide in tablets. In
general, both methods were found to be
suitable for routine quality control
analysis of the drugs in a combined
tablet dosage form.
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Table 1. Calibration graphs and system suitability (n = 5) of olmesartan medoxomil and hydrochlorothiazide by RP-LC and HPTLC
Parameter RP-LC HPTLC
OLM HCT OLM HCT
Linearity range 4–24 lgm L
-1 2.5–15 lgm L
-1 200–600 ng spot
-1 125–375 ng spot
-1
Regression equation
Slope 24,055 104,515 8.79 9.18
Intercept 688.3 -1,915.7 184.12 441.13
Coeﬃcient of correlation 0.9998 0.9999 0.9992 0.994
Limit of detection (LOD) 0.44 lgm L
-1 0.21 lgm L
-1 20.20 ng spot
-1 18.65 ng spot
-1
Limit of quantitation (LOQ) 1.32 lgm L
-1 0.63 lgm L
-1 61.07 ng spot
-1 57.24 ng spot
-1
System suitability
Asymmetry 1.75 1.22 – –
No. of theoretical plates 2,313 4,976 – –
Capacity factor 12.8 34.33 – –
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Table 2. Results of analysis of commercially available tablets containing olmesartan medoxomil
and hydrochlorothiazide by RP-LC and HPTLC
Method RP-LC HPTLC
OLM HCT OLM HCT
Labeled claim mg tablet
-1 20 12.5 20 12.5
% mean (n = 4) 100.24 100.1 100.09 99.77
Standard deviation 0.2926 0.3354 1.3123 1.6030
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SE standard error
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Fig. 2. Densitogram of olmesartan medoxomil (200 ng spot
-1, Rf 0.44) and hydrochlorothiazide
(125 ng spot
-1, Rf 0.64)
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